Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 3/20 | 0.38 |
| ▸ | KCNA2 | P16389 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.38 |
| ▸ | KCNA1 | Q09470 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217270 | 0.89 | KCNA2 (0.40) | KCNA3KCNA2KCNA5KCNA1PIM1 | |
| SCHEMBL23217471 | 0.81 | KCNA2 (0.39) | KCNA3KCNA2KCNA5KCNA1PIM1 | |
| SCHEMBL23217647 | 0.76 | CYP3A4 (0.44) | KCNA3KCNA2KCNA5KCNA1KCNA4 | |
| SCHEMBL23217807 | 0.75 | HDAC1 (0.34) | KCNA3KCNA2KCNA5KCNA1KCNA4 | |
| SCHEMBL23217508 | 0.74 | PTPN1 (0.38) | KCNA3KCNA2KCNA5KCNA1ALDH1A1 | |
| SCHEMBL30009850 | 0.74 | TBXAS1 (0.41) | KCNA3KCNA2KCNA5KCNA1PIM1 | |
| SCHEMBL29672939 | 0.74 | TBXAS1 (0.41) | KCNA3KCNA2KCNA5KCNA1PIM1 | |
| SCHEMBL23241692 | 0.74 | KCNA3 (0.42) | KCNA3KCNA2KCNA5KCNA1KCNA4 | |
| SCHEMBL23217665 | 0.73 | HTR2A (0.35) | KCNA3KCNA2SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL23241694 | 0.69 | KDM4E (0.39) | KCNA3KCNA2KCNA5KCNA1KCNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| CN-114555570-B | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | KCNA3 4001/4885KCNA2 4398/4885KCNA5 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.